NEW YORK (GenomeWeb News) – NanoString Technologies said after the close of the market on Tuesday that revenues for its second quarter rose 22 percent year over year.

The Seattle-based company, which went public in late June, raising $47.0 million in net proceeds, reported revenues of $7.2 million for the three months ended June 30, compared to $5.9 million a year ago, and beating the average Wall Street estimate of $6.8 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.